DekaBank Deutsche Girozentrale Has $380.21 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

DekaBank Deutsche Girozentrale trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 767,218 shares of the medical research company's stock after selling 5,425 shares during the period. Thermo Fisher Scientific comprises approximately 0.7% of DekaBank Deutsche Girozentrale's holdings, making the stock its 21st biggest holding. DekaBank Deutsche Girozentrale owned 0.20% of Thermo Fisher Scientific worth $380,206,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of TMO. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at about $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Cassady Schiller Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock worth $36,000 after purchasing an additional 33 shares during the last quarter. VSM Wealth Advisory LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $36,000. Finally, Navigoe LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 1.9%

NYSE TMO traded up $7.95 on Tuesday, reaching $426.65. The stock had a trading volume of 2,620,440 shares, compared to its average volume of 1,979,128. The stock has a fifty day moving average price of $409.13 and a two-hundred day moving average price of $478.65. The firm has a market capitalization of $161.06 billion, a price-to-earnings ratio of 25.02, a P/E/G ratio of 2.28 and a beta of 0.77. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same quarter in the prior year, the firm posted $5.11 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TMO shares. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. UBS Group cut their price target on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. Stifel Nicolaus lowered their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Evercore ISI cut their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, Argus dropped their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $603.05.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.